Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Antiviral Res. 2021 Aug 9;194:105160. doi: 10.1016/j.antiviral.2021.105160

Figure 2. Schematic of optimization assay.

Figure 2.

Serum percentage, multiplicity of infection (MOI), infection period, and β-galactosidase assay stability. Scheme of optimization process: 6,750 HepaRG cells were seeded in each well of 384-well plates with 1% or 2% FBS, incubated at 37°C in 5% CO2 for 24 hours. Cells were then infected with KOS6β or dlx3.1-6β at MOIs of 0, 0.2, 1, and 5. β-galactosidase levels were analyzed at 6 hpi, 12 hpi, and 24 hpi using CPRG. β-galactosidase stability was examined at 5, 35, 80, 120, and 1080 minutes.